(Q42694829)

5 November 2017

0 references

Maximizing the outcome of early ADMET models: strategies to win the drug-hunting battles? (English)

1 reference

5 November 2017

Jianling Wang

1

1 reference

5 November 2017

Alan Collis

series ordinal

2

1 reference

5 November 2017

language of work or name

English

0 references

publication date

19 March 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

5 November 2017

published in

1 reference

5 November 2017

volume

7

1 reference

5 November 2017

issue

4

1 reference

5 November 2017

page(s)

381-386

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Pharmaceutical profiling in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Comprehensive assessment of ADMET risks in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

ADME optimization and toxicity assessment in early- and late-phase drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Mitigating permeability-mediated risks in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Evolving molecules using multi-objective optimization: applying to ADME/Tox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

In vitro safety pharmacology profiling: what else beyond hERG?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

The Simcyp population-based ADME simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

A simple approach for indexing the oral druglikeness of a compound: discriminating druglike compounds from nondruglike ones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

Recent advances in physicochemical and ADMET profiling in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562199

10.1517/17425255.2011.562199

21 January 2018

Identifiers

DOI

1 reference

5 November 2017

1 reference